Last reviewed · How we verify
oxymetazoline-fluticasone propionate
This combination nasal spray uses a decongestant to reduce nasal swelling and a corticosteroid to suppress inflammatory responses in the nasal passages.
This combination nasal spray uses a decongestant to reduce nasal swelling and a corticosteroid to suppress inflammatory responses in the nasal passages. Used for Nasal congestion and symptoms of allergic rhinitis, Chronic rhinosinusitis with nasal obstruction.
At a glance
| Generic name | oxymetazoline-fluticasone propionate |
|---|---|
| Sponsor | Brian J Lipworth |
| Drug class | Nasal decongestant/corticosteroid combination |
| Target | Alpha-2 adrenergic receptor; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology/Rhinology |
| Phase | FDA-approved |
Mechanism of action
Oxymetazoline is an alpha-2 adrenergic agonist that causes vasoconstriction, reducing blood flow and edema in nasal tissues. Fluticasone propionate is a topical corticosteroid that inhibits inflammatory mediators and immune cell activation. Together, they provide both immediate symptomatic relief and sustained anti-inflammatory benefit for nasal congestion and rhinitis.
Approved indications
- Nasal congestion and symptoms of allergic rhinitis
- Chronic rhinosinusitis with nasal obstruction
Common side effects
- Nasal irritation or dryness
- Headache
- Epistaxis
- Rebound congestion (with prolonged use)
Key clinical trials
- Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea (PHASE4)
- Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation (PHASE4)
- ROTAHALER Device Optimization Study (PHASE1)
- Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis (PHASE1)
- Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects (PHASE1)
- An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers (PHASE1)
- A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (PHASE1)
- Relovair PD PK in Chinese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxymetazoline-fluticasone propionate CI brief — competitive landscape report
- oxymetazoline-fluticasone propionate updates RSS · CI watch RSS
- Brian J Lipworth portfolio CI